Corient IA LLC Invests $283,000 in Natera, Inc. $NTRA

Key Points

• Corient IA LLC has made a new investment in Natera, Inc., purchasing 2,000 shares worth approximately $283,000.
• Multiple large investors, including Price T Rowe Associates and SG Americas Securities, have significantly increased their stakes in Natera, reflecting strong institutional interest.
• Natera reported quarterly earnings with a revenue of $546.60 million, which exceeded analyst expectations, but posted a loss of ($0.74) EPS, missing estimates by ($0.14).

Corient IA LLC purchased a new stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 2,000 shares of the medical research company's stock, valued at approximately $283,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in NTRA. LRI Investments LLC acquired a new stake in shares of Natera in the fourth quarter valued at about $29,000. Bank of Jackson Hole Trust purchased a new position in shares of Natera in the first quarter worth about $29,000. Rakuten Securities Inc. raised its stake in Natera by 117.8% during the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after purchasing an additional 119 shares during the period. TCTC Holdings LLC raised its stake in Natera by 114.8% during the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock worth $33,000 after purchasing an additional 124 shares during the period. Finally, ORG Partners LLC purchased a new position in Natera during the first quarter worth about $32,000. Institutional investors and hedge funds own 99.90% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. UBS Group boosted their price target on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a report on Friday, May 9th. Royal Bank Of Canada boosted their price target on shares of Natera from $251.00 to $255.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Stephens restated an "overweight" rating and issued a $183.00 target price on shares of Natera in a report on Friday, August 15th. Finally, Cowen reaffirmed a "buy" rating on shares of Natera in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating and seventeen have issued a Buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $193.19.

Insider Buying and Selling at Natera

In other Natera news, Director Gail Boxer Marcus sold 4,299 shares of the firm's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $167.36, for a total transaction of $719,480.64. Following the completion of the transaction, the director directly owned 8,118 shares in the company, valued at approximately $1,358,628.48. This trade represents a 34.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Solomon Moshkevich sold 3,000 shares of the firm's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $157.07, for a total transaction of $471,210.00. Following the transaction, the insider owned 133,205 shares of the company's stock, valued at $20,922,509.35. This trade represents a 2.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 61,792 shares of company stock valued at $9,227,972. Insiders own 5.63% of the company's stock.

Natera Trading Up 2.3%

Shares of NTRA traded up $3.65 during trading hours on Friday, reaching $165.60. The company had a trading volume of 835,581 shares, compared to its average volume of 1,513,671. The firm has a 50 day simple moving average of $154.84 and a 200-day simple moving average of $154.38. Natera, Inc. has a 12-month low of $110.57 and a 12-month high of $183.00. The company has a market capitalization of $22.73 billion, a price-to-earnings ratio of -86.70 and a beta of 1.76.

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business had revenue of $546.60 million for the quarter, compared to analysts' expectations of $476.84 million. During the same quarter last year, the business posted ($0.30) earnings per share. The business's revenue was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.